RAPT THERAPEUTICS INC (RAPT) Stock Price, Forecast & Analysis
USA - NASDAQ:RAPT - US75382E2081 - Common Stock
RAPT Key Statistics, Chart & Performance
The current stock price of RAPT is 29.04 USD. In the past month the price decreased by -3.25%. In the past year, price increased by 25.61%.
RAPT Latest News, Press Relases and Analysis
RAPT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.18 | 386.95B | ||
| AMGN | AMGEN INC | 14.43 | 169.90B | ||
| GILD | GILEAD SCIENCES INC | 15.07 | 153.12B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.98 | 106.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.37 | 68.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 863.71 | 57.74B | ||
| INSM | INSMED INC | N/A | 39.25B | ||
| NTRA | NATERA INC | N/A | 27.24B | ||
| BIIB | BIOGEN INC | 9.36 | 22.98B | ||
| INCY | INCYTE CORP | 16.39 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.2 | 20.53B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 37.03 | 15.35B |
Related stock screener links
About RAPT
Company Profile
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company is headquartered in South San Francisco, California and currently employs 61 full-time employees. The company went IPO on 2019-10-31. The firm is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Company Info
RAPT THERAPEUTICS INC
561 Eccles Ave
South San Francisco CALIFORNIA 94080 US
CEO: Brian Wong
Employees: 61
Phone: 16504899000
RAPT THERAPEUTICS INC / RAPT FAQ
What does RAPT do?
Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company, which engages in the discovery, development, and commercialization of oral small molecule therapies for patients in oncology and inflammatory diseases. The company is headquartered in South San Francisco, California and currently employs 61 full-time employees. The company went IPO on 2019-10-31. The firm is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
What is the stock price of RAPT THERAPEUTICS INC today?
The current stock price of RAPT is 29.04 USD. The price increased by 2.72% in the last trading session.
What is the dividend status of RAPT THERAPEUTICS INC?
RAPT does not pay a dividend.
What is the ChartMill rating of RAPT THERAPEUTICS INC stock?
RAPT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of RAPT stock?
RAPT THERAPEUTICS INC (RAPT) operates in the Health Care sector and the Biotechnology industry.
Can you provide the ownership details for RAPT stock?
You can find the ownership structure of RAPT THERAPEUTICS INC (RAPT) on the Ownership tab.
What is the Short Interest ratio of RAPT THERAPEUTICS INC (RAPT) stock?
The outstanding short interest for RAPT THERAPEUTICS INC (RAPT) is 4.12% of its float.
RAPT Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to RAPT. When comparing the yearly performance of all stocks, RAPT is one of the better performing stocks in the market, outperforming 97.3% of all stocks.
RAPT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RAPT. No worries on liquidiy or solvency for RAPT as it has an excellent financial health rating, but there are worries on the profitability.
RAPT Financial Highlights
Over the last trailing twelve months RAPT reported a non-GAAP Earnings per Share(EPS) of -14.17. The EPS increased by 43.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -59.69% | ||
| ROE | -64.77% | ||
| Debt/Equity | 0 |
RAPT Forecast & Estimates
13 analysts have analysed RAPT and the average price target is 57.12 USD. This implies a price increase of 96.69% is expected in the next year compared to the current price of 29.04.